Insider Brief
- CIQ, the founding support partner of Rocky Linux, announced that biotechnology company FYR has selected its high-performance computing platform Fuzzball to power analytics workflows for AI-driven precision medicine.
- FYR’s EV-Omics platform uses AI to analyze extracellular vesicles and identify RNA and protein biomarkers, with Fuzzball enabling scalable, reproducible pipelines that accelerate biomarker discovery and drug development.
- Both companies are backed by Two Bear Capital, whose partner Mark Adams said the collaboration strengthens the firm’s mission to integrate advanced computing and life sciences to deliver faster, high-quality insights for patients.
PRESS RELEASE — CIQ, the founding support and services partner of Rocky Linux and a leader in high-performance software infrastructure, today announced that FYR, a biotechnology company leveraging extracellular vesicles (EVs) to create an end-to-end solution for new precision medicine tools, has selected Fuzzball, CIQ’s performance-intensive computing platform, to power its analytics workflows. FYR and CIQ are portfolio companies of Two Bear Capital, reflecting the firm’s commitment to backing transformative technology and life sciences innovation.
FYR utilizes AI-enabled multiomic insights through its EV-Omics (EVO) platform to unravel the complexities of disease mechanisms. By identifying RNA and protein biomarkers from EVs in blood, FYR uncovers novel disease insights, builds robust datasets to enhance clinical trials and delivers actionable guidance to accelerate drug development. The integration of CIQ’s Fuzzball amplifies this capability by enabling the speedy implementation of exploratory pipelines, allowing partners to interpret complex insights while maintaining the rigor and reliability of FYR’s proven platform. With Fuzzball, FYR can seamlessly scale AI models from laptop prototypes to production-ready analytics environments, delivering high-quality insights efficiently, reproducibly and at speed.
“FYR is doing groundbreaking work in applying AI to life sciences, and Fuzzball is the engine that enables these tools to operate at scale,” said Bjorn Hovland, chief operating officer at CIQ. “This partnership is a powerful example of how CIQ’s technology accelerates innovation while ensuring the reproducibility required for regulated environments.”
What This Partnership Delivers for Pharma and Biotech:
- Scalable, Reliable Solutions: Pharma and biotech companies often struggle to scale proven models beyond small pilot projects. Fuzzball bridges that gap, transforming validated workflows into production-ready, automated pipelines without requiring significant new infrastructure or technical headcount.
- Reproducibility: Regulatory compliance relies on consistent, repeatable results. With Fuzzball, workflows can be preserved and rerun exactly as originally executed, providing the confidence needed for GLP, GXP, and FDA-regulated environments, without sacrificing speed or quality.
- Strategic Value: Pharma and biotech companies face increasing pressure to modernize analytics and future-proof operations. By working with FYR, pharma partners gain immediate access to advanced multiomic insights, while CIQ’s Fuzzball provides the scalable foundation to expand and sustain those capabilities.
Additional benefits include rapid onboarding, with CIQ environments deployable in an hour instead of a day, and a stored catalog that preserves custom workflows for easy reuse.
“Building a production-quality pipeline used to take weeks when factoring in training and scaling,” said Claire Seibold, director of software and data analytics at FYR. “CIQ’s Fuzzball gives us the ability to implement and scale these pipelines for 100x the throughput in a fraction of the time. It delivers results to our pharma partners at the speed and scale that today’s innovation-driven discovery market demands, while providing the scalability and reproducibility needed to bring AI-driven biomarker discovery into real-world clinical practice. Being part of the Two Bear Capital portfolio enables us to collaborate with like-minded companies like CIQ, fostering transformative innovation across the life sciences ecosystem.”
“The partnership between FYR and CIQ demonstrates the impact of strategic collaboration,” said Mark Adams, Ph.D., partner at Two Bear Capital. “By integrating CIQ’s Fuzzball into FYR’s EV-Omics platform, these two companies can deliver faster, high-quality insights that accelerate biomarker discovery and advance precision medicine, ultimately generating meaningful outcomes for patients.”
Together, FYR and CIQ are advancing the next generation of precision medicine by pairing innovative AI tools with a high-performance computing platform purpose-built for scale, efficiency and reproducibility.
